Breast Cancer Clinical Trials in Houston

Showing 241-260 of 350 trials

Cancer Prevention and Treatment Demonstration for Ethnic and Racial Minorities

NCT00453661

The goal of this behavioral research study is to improve the use of cancer prevention services, increase early detection, and treatment of cancer. A secondary outcome of this demonstration project proposes that a structured patient navigator (PN) will reduce the cost of Medicare services.

Breast CancerCervical CancerProstate Cancer+2 more

M.D. Anderson Cancer Center2,472 participantsStarted Mar 2007

Houston, Texas, United States

COMPLETEDPHASE3< 1 mile

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

NCT01610284

This study was a multi-center, randomized, double-blind, placebo controlled Phase III study to determine the efficacy and safety of treatment with buparlisib plus fulvestrant versus fulvestrant plus placebo in postmenopausal women with hormone Receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative), locally advanced or metastatic breast cancer (MBC) whose disease has progressed on or after aromatase inhibitor (AI) treatment.

Breast Cancer

Novartis Pharmaceuticals1,147 participantsStarted Aug 2012

Mobile, Alabama, United States • Phoenix, Arizona, United States • Fayetteville, Arkansas, United States +265 more locations

Cancer Prevention and Treatment Demonstration for Ethnic and Racial Minorities

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Breast Cancer Trials in Other Cities

Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer

Primary Breast Cancer Occurring Concomitant With Pregnancy

A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer

Exemestane-RAD001-Metformin

A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer

Weight Gain Prevention for Breast Cancer Survivors

Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer

Lapatinib and Trastuzumab With or Without Endocrine Therapy

MRI to Detect Breast Tumors in Women

A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer

ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer

Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

Combination Chemotherapy in Treating Patients With Breast Cancer

Combination Chemotherapy and Trastuzumab in Treating Women With Metastatic Breast Cancer

MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

Other Conditions in Houston